Microbiota-based therapies for chronic kidney disease
- PDF  |
- DOI: https://doi.org/10.15562/ism.v10i1.239  |
- Published: 2019-05-01
Search for the other articles from the author in:
Google Scholar | PubMed | ISM Journal
Search for the other articles from the author in:
Google Scholar | PubMed | ISM Journal
Background: Increasing prevalence of chronic kidney disease (CKD) worldwide has been concerned as a global public health issue because of the burden of adverse outcomes, including mortality. Gut microbiota can be used as a potential therapeutic target to slow the progression of CKD.
Aim: This literature review aims to provide an in-depth review about the potency of microbiota-based therapy for CKD.
Method: from 58 journals reviewed, 51 were found suitable as references for this paper. The keywords used are “gut microbiota,†“chronic kidney diseaseâ€, “prebioticâ€, “probiotic†and “fecal microbiota transplantation†on selected search engines.
Result: In general, it has shown that microbiota-based therapies do have potential therapeutic effect as it can improve inflammatory response, uremic toxin, insulin resistance and cardiovascular risk.
Conclusion: Prebiotic, probiotic, fecal microbiota transplantation and novel therapies have shown beneficial effects in treating patients with CKD.